Dr. Wamhoff serves as HemoShear Therapeutics' Head of Innovation and is a company founder. He is responsible for development and management of strategic team initiatives to ensure a robust pipeline of disease models to advance our drug discovery platform and early stage therapeutic programs. Dr. Wamhoff has led teams to oversee the successful development of human vascular and liver disease models, as well as ongoing development of a tumor microenvironment system. These advancements have been built in part by his role in securing significant NIH Small Business Innovation Research funding from five different NIH institutes. Additional activities include scientific publication strategy and activities, thought leader development and engagement activities, and intellectual property and patent strategy. Dr. Wamhoff, former Associate Professor at the University of Virginia, has co-founded multiple medical device and therapeutics companies. He obtained a B.S. in biology with a minor in business administration from Rhodes College, where he was the 2011 Distinguished Alumnus; he received his Ph.D. in medical physiology from the University of Missouri.
Nikki Hastings, PhD, oversees HemoShear’s operations and infrastructure, has designed the company's state-of-the-art laboratory and office facilities, developed internal processes, and recruits staff and specialty service providers. Dr. Hastings expanded the core HemoShear technology for her doctorate work to investigate phenotypic changes critical to the initation of vascular disease. Dr. Hastings has a PhD in biomedical engineering from the University of Virginia and a B.S. in biomedical engineering from North Carolina State University.
Richard White is a CPA and tax professional and serves as the vice president of finance for HemoShear Therapeutics. Mr. White directs our financial, tax, and accounting activities. He founded his own tax and accounting firm in Charlottesville before joining HemoShear. Mr. White holds B.S. degrees in accounting and organizational behavior management from the University of Virginia.
Board of Directors
John L. Brooks, III, is the CEO of Arete Worldwide, LLC in Boston. He was previously the President and CEO of the Joslin Diabetes Center. He serves on the boards of Pathfinder Cell Therapy, Noxilizer, Ammonett Pharma, Longwood Energy Collaborative, Reflectance Medical, Inc., Suffolk University and Thermalin Diabetes. He was a founding partner of Prism Ventureworks. Prism has raised more than $1.25 billion and is based in Needham, MA. Mr. Brooks was formerly a general manager at Pfizer/Valleylab in Boulder, CO, where he developed and executed a minimally invasive surgery and emerging businesses strategy. Prior to Valleylab, he led the growth of a rapidly evolving vascular access medical device business at Pfizer/Strato Medical. Mr. Brooks has co-founded three paradigm-shifting life sciences companies: Songbird Hearing, Locus Pharmaceuticals and Insulet (PODD). He is a biotechnology advisory board member for Draper Labs. In addition, Mr. Brooks is a member of M2D2, an early-stage medical technology accelerator and a board member of the Massachusetts Technology Transfer Center (MTTC) advisory boards. He holds an MS in business and a BBA cum laude from the University of Massachusetts at Amherst. He is a certified public accountant and a certified financial planner.
H. Thomas Watkins is former Director, President, and CEO of Human Genome Sciences (HGS) from 2004 until HGS was acquired by GlaxoSmithKline in 2012. During his tenure, HGS successfully developed and brought Benlysta to market in 2011, the first new lupus drug to be introduced in 50 years. Prior to HGS, Mr. Watkins spent over 20 years in senior roles at Abbott and its affiliates in the U.S. and Asia. He was President of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc., where he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Previously, Mr. Watkins was a consultant with McKinsey and Company and Arthur Andersen. He is former Chairman of the Biotechnology Industry Organization (BIO) and continues to serve on its board. He is currently Chairman of the board of directors of Vanda Pharmaceuticals, Inc., and Vice Rector of the Board of Visitors of The College of William and Mary. Mr. Watkins received a B.B.A. in accounting from the College of William and Mary and his M.B.A. from the University of Chicago Graduate School of Business, now the Booth School of Business.
Robert J. Gould, Ph.D. is former President, Chief Executive Officer and current board member of Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients. He has held this position since March 2010, serving on the board of Epizyme from 2008 - 2010. Prior to joining Epizyme in March 2010, Dr. Gould was Director of Novel Therapeutics from 2007 - 2010 at The Broad Institute of MIT and Harvard. Dr. Gould spent 23 years at Merck & Co., Inc., a healthcare company, where he held a variety of leadership positions during his tenure there. As Vice President, Basic Research, he oversaw drug discovery activities for seven therapeutic areas, as well as Merck’s centralized high throughput screening facility. In addition, he spent three years as Vice President, Licensing and External Research. Dr. Gould received a B.A. in chemistry from Spring Arbor College, Michigan and a Ph.D. in biochemistry from The University of Iowa, Iowa. He also conducted post-doctoral studies in neuropharmacology at The Johns Hopkins University before joining Merck & Co., in 1981.
Mehmood Khan, MD, is the Vice Chairman of PepsiCo, Inc., where he is responsible for leading all aspects of the company’s research and development and product and equipment strategy. He provides global leadership and support to division research and development groups in the areas of enterprise research planning, R&D portfolio management, next generation technologies, nutritional standards, food safety and regulation and quality assurance. Prior to joining PepsiCo in 2007, Dr. Khan served as president of Takeda Global Research & Development Center, Inc. (TGRD). Dr. Khan has also served as consultant physician in Endocrinology and Director of the Diabetes, Endocrine and Nutrition Clinical Trials Unit in the Division of Endocrinology at the Mayo Clinic in Rochester, Minn.
Dr. Khan earned his MD from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a member of the Royal College of Physicians, London and a fellow of the American College of Endocrinology.
Reginald F. Woods was CEO of Butler International where he led a successful corporate turnaround that became the subject of three Harvard Business School case studies. The Butler companies generated significant earnings expansion through organic growth and acquisitions in their respective industries. Butler International was listed on the NYSE and was later acquired by a financial buyer at an attractive valuation. Mr. Woods then co-founded a merger and acquisition consulting practice specializing in the insurance industry. He is a founding Director of HemoShear Therapeutics, LLC, a founding Director and Chairman of Dynamic Literacy, LLC, and a Director of Scitent, Inc. He is on the Advisory Board of the University of Virginia Heart and Vascular Center, was co-founder of the Keswick Community Foundation, and has served on the board and executive committee of Habitat for Humanity of Greater Charlottesville. He earned B.S. and M.S. degrees in engineering and an M.B.A. from Cornell University.
W. McIlwaine (Mac) Thompson, Jr. is of counsel to the law firm of Woods Rogers PLC and specializes in representing companies in many diverse fields including biotechnology, information technology and oil and gas exploration. Mr. Thompson is secretary of Insmed Incorporated, a publicly traded biotechnology company, and is a member of the boards of Mestena Inc., an oil- and gas-exploration company, and Foundation Energy Management, LLC, which acquires oil- and gas-producing properties. He is a member of the investment advisory board of Tall Oaks Capital, a venture capital fund based in Charlottesville, and has represented many biotechnology companies in the Charlottesville area. He is also a member of the advisory board for the University of Virginia’s Heart and Vascular Center and general counsel to, and immediate past chair of, the board of the U.Va. Curry School of Education Foundation. Mr. Thompson graduated from Yale College in 1969 and the U.Va. Law School in 1972.
Gerald Fisher, PhD, began his career at the University of California, Davis in 1975 and progressed through several research positions focused on the area of inhalation toxicology. He joined Battelle in Columbus, OH in 1980 and during his nine years there advanced to the position of vice president of the Health and Environmental Effects Center. From 1989 to 1992, he served as vice president of drug safety and metabolism for Sandoz Research Institute in East Hanover, NJ. He joined Wyeth Pharmaceuticals in 1992 as vice president, drug safety and metabolism and was promoted to senior vice president in 1998. In January 2005, he assumed the role of chief preclinical scientist for Wyeth as senior vice president, Office of the President.
Dr. Fisher has a PhD in chemical ecology from the University of California, Davis, an MA from the University of California, Santa Barbara and a BA from Northeastern University. He has published more than 160 scientific papers, and he is the former editor of Drug and Chemical Toxicology and a member of the editorial boards of several pharmacology and toxicology journals.
John L. LaMattina, PhD, is the former senior vice president, Pfizer Inc. and president of Pfizer global research and development. In this role, Dr. LaMattina supervised the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. During his tenure, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. He retired from this position in December 2007. He is currently a senior partner at PureTech Ventures and also serves on the board of directors of Human Genome Sciences, the board of directors of Ligand Pharmaceuticals, the scientific advisory board of Trevena and the board of trustees of Boston College, where he chairs the Academic Affairs Committee.
Dr. LaMattina attended the University of New Hampshire working with Professor Robert E. Lyle and received a PhD from UNH in organic chemistry. He graduated cum laude from Boston College with a BS in chemistry. He is the author of numerous scientific publications and holds a number of U.S. patents. Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.
Mark L. Powell, PhD, retired from the pharmaceutical industry in 2011 after 32 years. He is currently a global consultant to the same industry. Prior to retirement, he was the senior vice president and worldwide head of non-clinical development (NCD) at Bristol-Myers Squibb. He was responsible for the worldwide planning and directing of all NCD activities for all BMS compounds (small molecules and biologics) in global development, as well as supporting globally manufactured products as necessary. Non-clinical development consisted of drug safety evaluation, early and late phase chemical development, chemical development operations, clinical supply operations, analytical and bioanalytical development, environmental health and safety, drug product science and technology and business operations and cmc writing. In addition to his functional responsibilities, Dr. Powell was the head of diabetes exploratory development at BMS from 2000-2005. In that capacity, he was responsible for the pharmaceutical, preclinical and clinical exploratory development and progression of all diabetes compounds transitioning out of discovery and into Phase III clinical development.
Dr. Powell has authored and co-authored more than 125 scientific articles and presentations which have been made at the local, national and international levels, as well as given numerous invited talks. He participated in, and moderated, many scientific discussion panels at both national and international meetings and has chaired an international scientific conference. In addition to his advisory role with HemoShear, he is currently a senior scientific consultant to Yangtze River Pharmaceuticals in China and WuXiApptech in China. Dr. Powell obtained his PhD from the University of Washington in 1980.
Robert Ruffolo, Jr., PhD, DSc, DEng, is the recently-retired president of research and development for Wyeth Pharmaceuticals, and corporate senior vice president of Wyeth. In that role, he managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. He joined Wyeth in 2000 as executive vice president responsible for pharmaceutical research and development, where he led the transformation of the Wyeth R&D pipeline and added many promising new drug candidates. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he was senior vice president and director of biological sciences, worldwide. Before joining SmithKline Beecham, Dr. Ruffolo spent six years at Lilly Research Laboratories, where he was chairman of the Cardiovascular Research Committee.
During his career in the pharmaceutical industry, Dr. Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including Carvedilol (Coreg/Kredex/Dilatrend) for the treatment of congestive heart failure, acute myocardial infarction and hypertension; Ropinerole (Requip) for Parkinson’s disease; Dobutamine (Dobutrex) for congestive heart failure; and Eprosartan (Teveten) for hypertension. Dr. Ruffolo has won numerous prestigious awards, including the 2008 Scrip Lifetime Achievement Award and the 2008 Discoverer’s Award for the discovery and development of Carvedilol (Coreg). Dr. Ruffolo received his PhD in pharmacology and his BS in pharmacy summa cum laude with distinction, both from The Ohio State University. He is the adjunct professor of pharmacology at The Ohio State University and adjunct professor of physiology and pharmacology at the West Virginia University School of Medicine.
Since his retirement, Dr. Ruffolo has been involved in various philanthropic endeavors. He and his wife underwrote the complete renovation of the Robert & Stephany Ruffolo Lecture Hall in the College of Pharmacy at his alma mater, The Ohio State University, and they have established endowed scholarships and/or fellowships at The Ohio State University, West Virginia University and the University of Florida. He also sits on the boards of directors for several biotechnology companies as well as non-profit charitable organizations.
Mervyn Turner, PhD, has more than 25 years of experience in pharmaceutical research and development, global licensing and strategy development. Dr. Turner retired recently from his position as Merck’s first chief strategy officer, where he drove strategy planning and resource allocation. As head of worldwide licensing & external research, he led the transformation of Merck & Co., Inc. to embrace external sources of innovation and collaboration. He was personally involved in more than 200 strategic transactions, including mergers and acquisitions. Prior to that, he was the site head for both Merck & Co. Inc.’s R&D facility in Rahway, NJ, and Merck Frosst, Canada.
Dr. Turner received a BS and PhD in chemistry from the University of Sheffield. He completed postdoctoral research on the biochemistry of histocompatibility at Harvard University.